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Abstract
Background: Chronic kidney disease (CKD) and end-stage renal disease (ESRD) represent worldwide health
problems with an epidemic extent. Therefore, attention must be given to the optimisation of patient care, as gaps
in the care of CKD and ESRD patients are well documented. As part of a multidisciplinary patient care strategy,
clinical pharmacy services have led to improvements in patient care. The purpose of this study was to summarise
the available evidence regarding the role and impact of clinical pharmacy services for these patient populations.
Methods: A literature search was conducted using the Medline, Embase and International Pharmaceutical Abstracts
databases to identify relevant studies on the impact of clinical pharmacists on CKD and ESRD patients, regarding
disease-oriented and patient-oriented outcomes, and clinical pharmacist interventions on drug-related problems.
Results: Among a total of 21 studies, only four (19%) were controlled trials. The majority of studies were
descriptive (67%) and before-after studies (14%). Interventions comprised general clinical pharmacy services with a
focus on detecting, resolving and preventing drug-related problems, clinical pharmacy services with a focus on
disease management, or clinical pharmacy services with a focus on patient education in order to increase
medication knowledge. Anaemia was the most common comorbidity managed by clinical pharmacists, and their
involvement led to significant improvement in investigated disease-oriented outcomes, for example, haemoglobin
levels. Only four of the studies (including three controlled trials) presented data on patient-oriented outcomes, for
example, quality of life and length of hospitalisation. Studies investigating the number and type of clinical
pharmacist interventions and physician acceptance rates reported a mean acceptance rate of 79%. The most
common reported drug-related problems were incorrect dosing, the need for additional pharmacotherapy, and
medical record discrepancies.
Conclusions: Few high-quality trials addressing the benefit and impact of clinical pharmacy services in CKD and
ESRD patients have been published. However, all available studies reported some positive impact resulting from
clinical pharmacist involvement, including various investigated outcome measures that could be improved.
Additional randomised controlled trials investigating patient-oriented outcomes are needed to further determine
the role of clinical pharmacists and the benefits of clinical pharmacy services to CKD and ESRD patients.
Background
Chronic kidney disease (CKD) represents a major public
health problem in developed and developing countries.
It is estimated that approximately 5% of the adult U.S.
population is affected by CKD, which is defined as
serum creatinine concentrations greater than 1.2 to 1.5
mg/dL [1]. The European Kidney Health Alliance
(EKHA) reports that approximately 10% of European
citizens are affected by some degree of CKD [2].
CKD and end-stage renal disease (ESRD) are asso-
ciated with an increased risk of mortality, increased rate
of hospitalisation, and decreased life expectancy [3]. Pro-
gression from early to late stages of CKD generally
results in the onset of new symptoms and concomitant
complications. Frequent complications and comorbid-
ities of CKD include fluid and electrolyte abnormalities,
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osteodystrophy, hypertension and hyperlipidaemia,
metabolic acidosis, and several other comorbidities
involving malnutrition, pruritus and uremic bleeding.
CKD patients are at increased risk of cardiovascular dis-
ease (CVD), which includes coronary heart disease
(CHD), cerebrovascular disease, peripheral vascular dis-
ease, and heart failure. The management of underlying
and evident comorbidities (either as causes or conse-
quences of CKD) and the prevention or delay of its pro-
gression to ESRD are complex.
In ESRD patients, the initiation of renal replacement
therapies (RRTs), such as long-term dialysis (including
haemodialysis (HD) or peritoneal dialysis (PD)) or trans-
plantation, is usually indicated to relieve uremic symp-
toms and detoxify, whereas kidney transplantation
(cadaveric or living donor transplantation) is the therapy
of choice for ESRD [4].
Multidisciplinary health care teams of physicians,
nurses, dieticians, and clinical pharmacists share the
goal of preventing disease progression and managing
comorbid conditions in CKD and ESRD patients. As
specialists in pharmacotherapy, clinical pharmacists are
routinely involved in patient care and interact with
other health care professionals, addressing multiple,
often unmet needs for pharmacotherapy optimisation.
Ideally, this happens through a preventive, rather than a
reactive, approach. Evidence from the literature supports
the involvement of clinical pharmacists in several dis-
ease areas and underlines the positive patient outcomes
and improvement of care that result [5,6].
The medical management of predialysis and dialysis
patients involves complex and highly variable pharma-
cotherapy, including frequent monitoring and evaluation
to ensure optimal pharmacotherapy, adherence to medi-
cation, and control of comorbidities and other risk fac-
tors. A high number of prescribed medications, poor
medication adherence, and frequent dosage changes
may contribute to drug-related morbidity and related
problems [7]. Several studies report poor quality and
gaps in the care of CKD patients with respect to the
treatment of comorbidities, referrals to specialists, and
the preparation for RRTs [8,9].
Clinical pharmacists are directly engaged in the care of
CKD and ESRD patients in different settings. Various
possibilities and opportunities for clinical pharmacists to
contribute to this field are described and exemplarily
supported by evidence in an American College of Clini-
cal Pharmacy (ACCP) opinion paper [10].
This literature review aims to systematically summar-
ise the published evidence on the role of clinical phar-
macists in the care of CKD and ESRD patients across
different settings, to synthesise and highlight findings on
the impact of clinical pharmacists, their various key
activities, and their main areas of involvement, and to
describe the different characteristics of clinical pharmacy
services for the CKD and ESRD patient population.
Methods
A literature search was conducted using the Medline
(1970 - Week 46, 2010), Embase (1996 - Week 45,
2010) and International Pharmaceutical Abstracts (IPA)
(1970 - Oct 2010) databases to identify relevant articles.
In Medline, the following combinations of Medline
Medical Subject Headings (Mesh) terms were used as
our search strategy: ("pharmacy service, hospital” OR
“pharmacists” OR “pharmaceutical services”)A N D
("renal insufficiency” OR “kidney” OR “renal replace-
ment therapy”). In Embase and IPA, the search strategy
combined the terms ("clinical pharmacy” OR “pharma-
ceutical care” OR “pharmacist” OR “hospital pharmacy”)
AND ("renal insufficiency” OR “kidney” OR “renal repla-
cement therapy”). The references sections of the
returned publications and review articles were further
screened for additional hits. Data were extracted and
reviewed by the first study author (GS) and indepen-
dently reviewed by the second author (RLG). Discrepan-
cies were solved by discussion among the study authors.
All studies addressing the impact of clinical pharmacy
services (either at the patient or the physician level) on
the care of CKD and ESRD patients for both HD and
PD were included. Therefore all studies reporting on
disease-oriented and patient-oriented outcomes, and
clinical pharmacist interventions on drug-related pro-
blems (DRPs) together with the physician acceptance
rate, were assessed. Studies addressing the impact of
clinical pharmacy services in kidney transplantation
were excluded. A detailed review of these kinds of ser-
vices was recently published [11]. Detailed inclusion and
exclusion criteria are described in Table 1. The weakest
study design included was observational and solely
descriptive, as a high number of randomised controlled
trials could not be anticipated. Results published in
abstract form (e.g., congress abstracts) were included
only if they provided numerically assessable data, such
as outcome data, the number of resolved DRPs, or phy-
sician acceptance rates.
Predefined data parameters (namely, the study design,
duration and setting, the number of included patients,
the types of interventions, the relevant outcomes, the
results, and available statistical values) were extracted
from the literature, summarised in an Excel spreadsheet,
and reviewed.
Results
The initial Medline, Embase and IPA searches yielded
339, 199, and 323 citations, respectively. The detailed
search results are described in Figure 1.
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Page 2 of 12A total of 861 citations were initially screened for
inclusion criteria, and after removing duplicates, a total
of 21 citations remained for full review and analysis.
The predominant reason for exclusion was a lack of
interventional and/or assessable data. Several initial cita-
tions had to be excluded because they provided data
only on the impact of screening on appropriate renal
dosing, with or without computerised support, or they
provided only economic data.
General study characteristics
Detailed descriptions on the included studies of CKD
and ESRD patients, including relevant interventions,
outcomes, and results, are shown in Tables 2 and 3,
respectively. Three study types were identified, including
14 descriptive studies (DSs) (66.7%), four (randomised)
controlled (R)CTs (19%), and three before-after studies
(BASs) (14.3%). A total of seven (33.3%) of the published
s t u d i e sw e r eo n l ya v a i l a b l eas abstracts. The earliest
included study was published in 1993. The study sites
were predominantly located in the United States (n =
16, 76.2%). The majority of the studies investigated the
impact of the clinical pharmacist on the HD patient
population only (n = 15, 71.4%). Six studies (28.6%)
addressed care issues in CKD patients. Only two studies
(9.5%) [12,13] included PD patients. Most of the studies
were performed in an ambulatory HD or CKD patient
care setting (n = 17, 81%), whereas only four studies
contained data on in-hospital clinical pharmacist activ-
ities (see Tables 2 and 3). Using data from 18 reported
studies, the median (range) number of study participants
was 60 (10-408), and the median (range) study duration
was six (1-32) months.
Scope of clinical pharmacy activities
The interventions performed in the included studies
could be roughly grouped into the following categories:
(1) general clinical pharmacy services (n = 12, 57.1%)
[12-23], (2) clinical pharmacy services focusing on dis-
ease management (n = 7, 33.3%) [24-30] and (3) clinical
pharmacy services with a focus on educational activities
(n = 2, 9.5%) [31,32]. A listing of reported clinical phar-
macist activities is provided in Table 4. The included
studies report on the clinical pharmacists’ involvement
in the management of anaemia, lipid disorders, cardio-
vascular disease, hypertension, and diabetes in CKD or
ESRD patients to various extents.
Outcomes
In 47.6% (n = 10) of the included studies [13,16,24-31],
disease-oriented outcomes were reported, whereas
patient-oriented outcome da t aw e r eo n l ya v a i l a b l ei n
four studies (19%) [22,23,31,32]. A synthesis of the dis-
ease- and patient-oriented outcome data is shown in
Table 5. Four controlled trials (three of which were ran-
domised) revealed that clinical pharmacy interventions
had a positive impact on patient-oriented outcomes in
the intervention group as compared to the available
standard of care.
The third type of outcome parameter in the included
studies was the total number of clinical pharmacist
interventions performed or recommendations given
together with the physician acceptance rate. These were
considered primary (n = 7) or additional secondary (n =
3) outcome parameters in 10 out of 21 (47.6%) studies.
In the subanalysis of DSs, a weighted mean acceptance
rate (± SD) based on study size of 78.7% (± 19.5) was
calculated. DRPs were mainly classified according to the
Table 1 Inclusion and exclusion criteria for literature search
Included Excluded
Study types (Randomized) controlled trials ((R)CTs), descriptive studies (DS), before-after
studies (BAS) with interventional data
Case reports, case studies, surveys, cost-effectiveness
studies, narrative reviews
Interventions Any type of clinical pharmacist intervention embedded in comprehensive
clinical pharmacy activities if data were assessable numerically and
outcomes were reported
Solely screening for inappropriate renal dosing,
evaluations of computerised decision support systems
Language Publications in English and German Any other language
Initial Databases Search: 861
Medline (339)
Embase (199)
IPA (323)
Abstract selection: 27
Medline (13)
Embase (3)
IPA (11)
Articles included: 20
Total articles: 21
Articles added: 1
Application of inclusion/
exclusion criteria
Removing of duplicates
Figure 1 Flowchart of search strategy and results.I P A
International Pharmaceutical Abstracts.
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Page 3 of 12Table 2 Detailed description of the included publications on CKD patients
First author,
(Year),
Population
Design N
(INT/CT)
a
Duration
(months)
Interventions Relevant outcomes
b Results p-Value
Lim SB et al.
[14], (2003),
CKD inpts
DS 60 2 MR, therapeutic monitoring,
feedback to physicians
No./Types of DRPs 86
Abstract Transcription errors 44%
Renal dosage adjustments 10%
PhAR 93%
Significance
Somewhat significant 26%
Significant 67%
Very significant 4%
Patel HR et al.
[15], (2005),
CKD outpts
DS 119 NR Review of medical records,
evaluations of DRPs,
therapeutic
recommendations
No. of DRPs 381 (100%)
Abstract Types of Interventions
Change of drugs NR
Change of dosage NR
Interval adjustments NR
PhAR 40.9%
Allenet B et al.
[31], (2007),
CKD outpts
BAS 10 3 Pharmacist-managed
anaemia educational
programmes
Knowledge (% of right answers on a 7-
item questionnaire) at baseline vs.
follow-up at Month 3
80 ± 18/93 ± 10 NS
QOL judged on a LAS (0-10) at baseline
vs. Month 3
Energy 3.3 ± 1.7/
7.1 ± 1.7
< 0.05
Daily activities 4.9 ± 2.1/
7.7 ± 1.9
< 0.05
General well-being 4.6 ± 2.2/
7.5 ± 1.6
< 0.05
Bucaloiu ID
et al. [24],
(2007), CKD
outpts
DS NR 32 Pharmacist-managed
anaemia programmes
compared to PCP-managed
pts
Weekly erythropoietin dose 6.698/12.000 units 0.0001
Abstract Time to achieve Hb goal 47.5/62.5 days 0.11
Maintenance of Hb values in target
range
69.8/43.9% 0.0001
Maintenance of Tsat values in target
range
64.8/40.4% 0.043
Joy MS et al.
[25], (2007),
CKD outpts
DS 128 28 Clinical pharmacist-
managed anaemia
programmes with
darbopoietin
% of pts achieving Hb target compared
to retrospective baseline analysis of data
(before clinical implementation)
78/41%
Lee J et al.
[16], (2009),
CKD outpts
CT 18 (9/9) 6 INT: PC
CT: SOC
Disease control parameters: Change
from baseline to last follow-up visit
(INT/CT)
Abstract Blood pressure -6/+6.8 mmHg
HbA1c -0.2/0%
Haemoglobin 1.05/-1.85 g/dL
Medication adherence (pill count) 97.2/88.2%
BAS before-after study, CKD chronic kidney disease, CT controlled trial, DS descriptive study, DRP drug-related problem, Hb haemoglobin, HbA1c glycosylated
haemoglobin, LAS linear analogue scale, MR medication review, No. number, NR not reported, NS not significant, PC pharmaceutical care, PCP primary care
physician, PhAR physician acceptance rate, pts patients, QOL quality of life, SOC standard of care, Tsat transferrin saturation
a Number of included patients in the intervention (INT) or control (CT) group
b For brevity, only the three most commonly performed interventions/drug-related problems are listed.
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Page 4 of 12Table 3 Detailed description of the included publications on dialysis patients
First author,
(Year),
Population
Design N
(INT/
CT)
a
Duration
(months)
Interventions Relevant outcomes
b Results p-
Value
Tang I et al.
[17], (1993),
HD outpts
DS NR 6 Therapeutic interventions provided by
CP
No./Types of
interventions
205 (100%)
Abstract Drug selection 66 (32.2%)
Drug
discontinuation
39 (19.0%)
Dose selection 50 (24.4%)
Significance of
interventions
Preservation of
major organ
function
34.6%
Improvement in
quality of care
62.4%
PhAR 91.7%
Kaplan B et al.
[18], (1994),
HD outpts
DS 24 NR Focused DT review programmes No. of
recommendations/
informative comments
114/85
Abstract PhAR 76% (implemented 70%)
Grabe DW et
al. [19], (1997),
HD outpts
DS 45 1 DT reviews by CP
Therapeutic recommendations
No./Types of DRPs 126 (100%)
Drug interactions 35 (27.5%)
Dialysis-specific
DRPs
33 (26.5%)
PhAR 81%
No. of interventions 102
1 - adverse
significance
0%
2 - no significance 6.9%
3 - somewhat
significant
0%
4 - significant 78%
5 - very significant 4.9%
6 - extremely
significant
1%
Possidente CJ
et al. [12],
(1999), HD
and PD inpts
DS 37 3.5 CPS (MR, pts interviews, identification
and resolution of DRPs)
No./Types of DRPs 161
Pts did not receive
drug
Overdosage
Labs needed
More DRPs (77) at admission
vs. discharge (41)
< 0.011
PhAR 95.7%
Significance
Somewhat
significant
24.7%
Significant 58.4%
Very significant 16.9%
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Page 5 of 12Table 3 Detailed description of the included publications on dialysis patients (Continued)
To LL et al.
[26], (2001),
HD outpts
BAS 49 6 Pharmacist-managed programmes
compared to physician-managed pts
Mean HCT (± SD)
during physician
period vs. pharmacist
period
35.36 ± 3.33/36.21 ± 3.46% 0.20
Total EPO ? dose 8.5/7.7 million units 0.37
Total elemental iron
dose oral
85.605/95.550 mg 0.64
Total elemental iron
dose i.v.
13.600/33.025 mg < 0.001
Mean (± SD) Tsat level 29.82 ± 14.92/30.78 ± 13.17% 0.66
Viola RA et al.
[27], (2002),
HD outpts
DS 26 6 Pharmacist-managed hyperlipidaemia
programmes with HD pts (laboratory
management, counselling, statin
initiation, and adjustments)
% of pts achieving
LDL cholesterol target
at baseline vs. Month
6
58%/88% 0.015
Mean LDL (± SD)
cholesterol at baseline
vs. Month 6
96c5/80 ± 3 mg/dL < 0.01
Mean total cholesterol
(± SD) at baseline vs.
Month 6
170 ± 7/151 ± 4 mg/dL < 0.01
No./Types of
interventions
15
Dose increase 6
Drug change 5
Therapy initiation 2
Kimura T et al.
[28], (2004),
HD outpts
DS 41 9 Pharmacist-managed anaemia
programmes
No. pts achieving the
HCT target of >30% at
baseline vs. Month 9
7 (17.1%)/32 (78%)
No. pts with EPO dose
reductions due to
intervention
23 (56%)
Manley HJ et
al. [29], (2004),
HD outpts
Abstract
DS 408 NR Implementations of treatment
algorithms for CV disease in HD pts by
a pharmacist, collections of CV
medication-related issues and
recommendations to nephrologists, pts
interview, MR
No. of
recommendations
1575
PhAR 79.8%
Impact of
recommendations on
pts care
Improvement 89.9%
No impact 7.6%
Worsened pts care 2.4%
LDL cholesterol -31.2 mg/dL < 0.001
HbA1C -0.3% NS
Adjusted CV mortality
hazard ratio
0.48 (CI 0.18, 1.3)
Walton T et
al. [30], (2005),
HD outpts
DS 278 26 Pharmacist-managed anaemia
programmes
Hb value at baseline
and Month 6
9.5/11.8 g/dL
Mean (± SD) ferritin at
baseline and Month 6
280.9 ± 326.4/431 ± 232.1
ng/mL
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Page 6 of 12Table 3 Detailed description of the included publications on dialysis patients (Continued)
Mean (± SD) Tsat at
baseline and Month 6
21 ± 7.9/33 ± 8%
Sathvik BS et
al. [32], (2007),
HD outpts
RCT 90 4 Pharmacist-provided pts education Medication
knowledge (MKAQ) at
baseline, Month 2 and
4 in Group 1 and 2
Improvement in MKAQ scores
in Group 1 compared to
baseline and to Group 2 at
Month 2
< 0.05
Group 1: Pharmacist pts education
(Month 0-2)
No significant improvement
in MKAQ scores in Group 2
compared to baseline at
Month 2
>0.05
Group 2: Usual health care w/o
pharmacists (Month 0-2)
Improvement in MKAQ scores
in Group 2 at Month 4
compared to baseline and to
scores at Month 2
< 0.05
Switch at Month 2 Decrease in MKAQ scores in
Group I at Month 4
compared to Month 2
< 0.05
Erickson AI et
al. [20], (2008),
HD in- and
outpts
DS 1184
pts
visits
4 Prospective order review by CP and
general CPS
Compliance with
prospective order
review
1059 (89.4%)
No./Types of
interventions
77 (100%)
Therapeutic-
related
11 (14.3%)
Safety-related 49 (63.6%)
Compliance-
related
17 (22.1%)
PhAR 100%
Castro R et al.
[13], (2009),
HD in- and
outpts
BAS 60 6 MTM Disease control
parameters at baseline
vs. follow-up visit at
Day 90
Abstract SBP (MTM) 150 ± 22/144 ± 18 mmHg 0.12
SBP (non-MTM) 143 ± 21/145 ± 25 mmHg NS
HbA1c (MTM) 9.2 ± 1.6/9.0 ± 2.0% 0.58
HbA1c (non-MTM) 6.2 ± 1.2/6.5 ± 1.4% NS
Phosphorus (MTM) 6.2/5.6 mg/dL .096
Calcium/phosphorous
product (MTM)
56 ± 19/50 ± 16 .03
Mirkov S [21],
(2009), HD
outpts
DS 64 8 DT reviews by CP No./types of DRPs 278 (100%)
Non-adherence 61 (22%)
Overdosage 26 (9.3%)
Untreated
indication
24 (8.6%)
Pai AB et al.
[22], (2009),
HD outpts
RCT 104
(57/
47)
24 INT: PC, DT reviews by CP No./Types of DRPs 530 (100%)
CT: SOC, DT reviews by dialysis nurse Drug record
discrepancy
133 (25%)
Untreated
indication
111 (21%)
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Page 7 of 12system presented by Strand et al. [33]. However, in sev-
eral included studies, information on classification meth-
odology was scarce, or a system developed by the
authors was used. The DRPs most frequently described
in the included studies were untreated indications,
super- or supratherapeutic dosages and consequent dose
adjustments, and medication record discrepancies.
Assessments of the clinical significance of clinical phar-
macist interventions were performed and reported in
five of 10 included studies. For this purpose, the signifi-
cance criteria published by Hatoum et al. [34] was used
in two studies [12,19]. Unspecified categorisation sys-
tems were used in the other studies. Bias minimisation
methods used during clinical significance assessments
generally included a review by independent clinical
pharmacists or the achievement of consensus among the
ratings of clinicians, nephrologists and pharmacists.
Information on the drug classes among which the
clinical pharmacists detected the majority of DRPs was
reported in four of 10 studies [12,19,22,23]. The most
commonly affected drugs were those used for treatment
against renal bone disease and renal osteodystrophy
together with anaemia and cardiovascular drugs.
The most common comorbidity in CKD or ESRD
patients managed by clinical pharmacists was anaemia.
Clinical pharmacists were primarily responsible for
ordering and checking laboratory values and managing
independent dosing and dose modifications of erythro-
poiesis-stimulating agents (ESAs) and iron within specific
prescribing guidelines. Furthermore, comprehensive dis-
ease management programmes also included patient
education and adherence-enhancing activities. Most of
the studies [16,24,25,27-30] reported that a significantly
higher proportion of patients managed by a clinical phar-
macist maintained relevant target ranges (e.g., haemoglo-
bin and haematocrit) as compared to patients receiving
standard care. Aside from two studies addressing lipid
management [27] and cardiovascular risk reduction in
HD patients [29] through multiple disease interventions,
no studies on diseases common to CKD or ESRD patients
(e.g, hypertension or secondary hyperparathyroidism) or
disease progression factors (e.g., proteinuria) with applic-
able inclusion criteria could be identified.
Discussion
Our systematic review synthesises evidence on the
impact of clinical pharmacist involvement in DRPs in
general, with respect to different comorbidities (e.g.,
anaemia and lipid management), and regarding educa-
tional issues in CKD and ESRD patients.
Evidence of gaps in the care of patients with renal
impairment (e.g., poor hypertension control, anaemia
control in CKD and dialysis patients) is published in the
literature [8,9]. For the patient’s sake, these gaps must
be addressed using all available methods. Enhancing the
involvement of clinical pharmacists may be one poten-
tial strategy. Thus, for example, clinical pharmacist-led
programmes showed higher proportions of CKD
patients achieving haemoglobin target [25], increased
medication knowledge [32], decreased hospitalisation
rates [22], and an overall improvement in the quality of
life of dialysis patients [23].
Table 3 Detailed description of the included publications on dialysis patients (Continued)
Subtherapeutic
dosage
74 (14%)
PhAR 100%
Reduction in drug use
in INT
14% < 0.05
Reduction of
hospitalisations in INT
42% 0.02
Reduction of LOS in
INT
21% 0.06
Pai AB et al.
[23], (2009),
HD outpts
RCT 107
(61/
46)
24 INT: PC, DT reviews by CP Total RQLP scores at
Year 1 compared to
baseline INT/CT
Worsening in Total RQLP
score at Year 1 in CT group
(88 ± 31/71 ± 34)
0.03
CT: SOC, DT reviews by dialysis nurse Total RQLP scores at
Year 2 compared to
baseline INT/CT
Improvement in INT/CT
group, no statistically
significant difference
BAS before-after study, CP clinical pharmacist, CPS clinical pharmacy services, CV cardiovascular diseases, DRP drug-related problem, DS descriptive study, DT
drug therapy, EPO erythropoietin, HbA1c glycosylated haemoglobin, HCT haematocrit, HD haemodialysis, Hb haemoglobin, LDL low-density lipoprotein, LOS
length of stay, MKAQ medication knowledge assessment questionnaire, MR medication review, MTM medication therapy management service, No. number, NR
not reported, NS not significant, PC pharmaceutical care, PhAR physician acceptance rate, pts patients, RCT randomised controlled trial, RQLP renal quality of life
profile, SBP systolic blood pressure, SD standard deviation, SOC standard of care
a Number of included patients in the intervention (INT) or control (CT) group
b For brevity, only the three most commonly performed interventions/drug-related problems are listed.
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Page 8 of 12By addressing the issues illustrated in Table 4 in their
general and more specified clinical work, clinical phar-
macists fulfil the requirements stated in the NKF-
KDOQI Guidelines “Chronic Kidney Disease: Evaluation,
Classification and Stratification” [35], which explicitly
highlight the need for regular medication reviews,
including dosage adjustment, adverse drug event (ADE)
detection, drug interaction detection, and therapeutic
drug monitoring (TDM). Given the nature of their
major responsibilities and tasks, clinical pharmacists
interact with patients, physicians, and other health pro-
fessionals and share the goal of optimising pharma-
cotherapy and patient care. This multidisciplinary and
multilevel approach is underlined by all included studies.
Clinical pharmacists, as pharmacotherapy experts, are
engaged in the care of the CKD and ESRD patient
population at different stages. Potential responsibilities
of clinical pharmacists may comprise attainment of
blood pressure, glycaemic, and lipid goals, and the early
evaluation and treatment for proteinuria, anaemia, and
secondary hyperparathyroidism, among others [10].
Optimal control of hyperglycaemia, including maximal
suppression of urinary albumin excretion by angioten-
sin-converting enzyme inhibitors (ACEIs) or angiotensin
II receptor blockers (ARBs) in diabetic patients with
persistent microalbuminuria, and hypertension can limit
progression of CKD to ESRD. Evidence of improved gly-
caemic and blood pressure control and decreased levels
of microalbuminuria through clinical pharmacists’ invol-
vement in patient care is published [36-38]. However,
due to our search strategy, studies explicitly addressing
only these latter aspects are not included in this sys-
tematic review. Furthermore, no study of clinical phar-
macy services in CKD patients investigating the slowing
down of disease progression could be identified.
The CKD and ESRD population can be characterised
by its vulnerability and susceptibility to drug-therapy-
related morbidity due to many factors. Commonly
reported DRPs in CKD or ESRD patients (e.g., dosing
problems and medical record discrepancies) are not sur-
prising given the complexity of dosing during either
type of renal replacement therapy due to common
changes in drug pharmacodynamics and pharmacoki-
netics [39]. This fact is further aggravated by the high
number of concomitant drugs used and comorbidities,
as studies report an average number of 10 to 12 drugs
per day and five comorbidities for HD patients [7].
Table 4 Comprehensive listing of clinical pharmacy activities performed in CKD and ESRD patients
Medication review and monitoring of
patient’s pharmacotherapy regimen
Education and counselling Disease management
programmes
Further
tasks
Taking a thorough medication history, including
OTC drugs, herbal supplements, drugs
prescribed by non-nephrologists, and CAM
drugs
Provision of medical and therapeutic
information for patients and other health care
professionals
Basic clinical assessments during
patient visists
Medication
use
evaluation
Medication review at different time points, such
as at admission, during inhospital treatment,
during each dialysis session, and at discharge
Training regarding the administration of drugs
(e.g. ESAs self injections)
Ordering of laboratory tests Audit
measures
Matching computerised medication profiles
with verbally obtained medication history
Counselling on side effects, interactions Co-ordering of anaemia therapies
and other drugs
Medication order review and checking
adherence to prescribing guidelines
Compiling of guidelines for proper drug use (e.
g., iron and ESAs) and implementation of
treatment algorithms (e.g., hyperlipidaemia,
hypertension, and renoprotective drugs)
Co-prescribing within the scope of
specific guidelines (e.g., anaemia
management or lipid
management)
Development of discharge medication plans Assessment and monitoring of compliance and
adherence
Identification of potential or actual DRPs
Therapeutic recommendations (e.g. change of
drugs, dose and/or interval adjustments,
discontinuation of drugs, additional laboratory
monitoring, nephrologist referral, addition of
renoprotective drugs)
Therapeutic monitoring (treatment, laboratory
values, and specific drugs)
Table 5 Disease versus patient-oriented outcomes
Disease-oriented outcomes Patient-oriented
outcomes
Total cholesterol, LDL, HDL Rate of hospitalization
HbA1c Length of stay
Haematocrit, Tsat, ferritin, haemoglobin Health-related quality of
life
SBP, DBP Medication-related
knowledge
Phosphorus, calcium-phosphorus product Renal quality of life
Drug dosages (e.g., EPO dosage or ferrous
dosage)
Patient satisfaction survey
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for patients taking more than five drugs, patients with
more than 12 total medication doses, patients with drug
regimens prone to frequent changes and three or more
concurrent disease states, and patients with a history of
non-compliance, and the presence of drugs requiring
TDM [40]. CKD and HD patients generally fulfil all of
these criteria and therefore warrant increased monitor-
ing. Problems with medical record discrepancies and the
accuracy of medication profiles, which are among the
most commonly reported DRPs, are further highlighted
in a prospective observational study of 63 HD patients,
which reports record discrepancies in 60% of all
patients. Several clinical pharmacy studies provide
insights into the risk factors for DRPs. One study [15]
highlights an inverse correlation between residual kidney
function (based on creatinine clearance) and the number
of DRPs. Another study reports a positive correlation
between the number of DRPs, on the one hand, and age
and length of time on dialysis, on the other [21]. All of
these aspects present opportunities for clinical pharma-
cist to engage in CKD and ESRD patient care.
Generally, more than three-quarters of clinical phar-
macist interventions and suggestions were accepted by
physicians. This physician acceptance rate is well within
the range of other reported acceptance rates based on a
review of clinical pharmacist impact on DRPs and clini-
cal outcomes [6]. Due to the use of different classifica-
tion systems and the resulting heterogeneity of DRPs, a
profound statistical analysis was not performed.
No studies could be identified that explicitly addressed
the issue of adherence in CKD or ESRD patients; none-
theless, it presents a major barrier to optimal patient
care. Especially among patients taking a high number of
prescription drugs, complex medication schemes and
long treatment periods caus ea d h e r e n c et ow a n e[ 4 1 ] .
Guaranteeing a high level of medication knowledge may
be one strategy to increase adherence and to prevent
DRPs resulting from incorrect drug use or overall failure
to take medications. Clinical pharmacist intervention to
improve patient medication knowledge was the study
objective in two of the included studies [31,32], which
could be achieved.
We identified a higher proportion of studies investi-
gating disease-oriented versus patient-oriented out-
comes. Patient-oriented outcomes are those that directly
matter to patients, that is, those regarding longer life
and improved quality of life. From an evidence-based
point of view, studies investigating patient-oriented out-
comes contribute more to the overall evidence and
therefore have to be weighted more heavily. However,
further studies with hard endpoints, as highlighted in
Table 5 as well as longer study periods are definitely
warranted, as they provide further evidence on the role
of pharmacists in the care of CKD and ESRD patients
and other patient groups.
Several studies on clinical pharmacist involvement
were identified by our search strategy, but only four of
them were controlled trials (two by the same authors)
with high-quality methodological design and therefore a
higher evidence impact. We decided to also include
abstracts in our review, because we are convinced that
these small studies of the impact of clinical pharmacy
on patient care contribute to the overall evidence on
this topic. We could not identify any studies that specifi-
cally addressed PD patients. However, in the two studies
that included PD patients, the authors did not comment
on any special issues (e.g., regarding the type of DRPs
or adherence). Given the complexity and specifics of
drug dosing during PD, the high need for education and
patient training, and the high risk of infections (e.g.,
peritonitis), data specific to this patient population
would be interesting and warranted. We hypothesise
that clinical pharmacists are routinely integrated into
different aspects of PD patient care, but due to irregular
clinical attachment (as compared to HD patients, who
generally attend clinic three times per week), such stu-
dies are more difficult to perform.
Furthermore, regarding CKD patient studies, it was not
possible to subdivide different clinical pharmacist activ-
ities and further relevant findings (e.g., common DRPs
and performed interventions) according to CKD stage.
Our review is subject to publication bias. We could not
identify any studies showing that clinical pharmacy inter-
ventions had a negative impact on patient care. Further-
more, studies that used DRPs and physician acceptance
rates as outcome parameters lacked information about
rejected interventions and the reasons for rejection. The
reporting of clinical significance assessments for per-
formed interventions increases the scientific value of clin-
ical pharmacy research, primarily by reducing bias. Data
on the impact of clinical pharmacists on hospitalised
inpatients is also scarce. In addition, the majority of the
studies were published in the United States. Interestingly,
only one study [31] from Europe could be identified;
three of the remaining four studies were from Asia
[14,28,32], and one was from New Zealand [21]. How-
ever, we hypothesise that clinical pharmacists are widely
engaged in the care of CKD and ESRD patients. There
are, for example, special interest groups dedicated to
their care, such as the United Kingdom Renal Pharmacist
Group [42]. Further high-quality studies on the impact of
clinical pharmacists on key issues such as adherence and
disease progression are thus warranted.
Conclusions
All identified studies on the involvement of clinical
pharmacists in the care of CKD and ESRD patients
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Page 10 of 12showed some benefit. However, high-quality evidence on
the impact of clinical pharmacy services is limited to a
few studies. Clinical pharmacists address areas requiring
improvement as well as unmet DRPs responsively and
preventatively. By doing so, clinical pharmacists posi-
tively contribute to the care of patients with impaired
renal function and reduce the gaps in current patient
care.
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